toggle visibility Search & Display Options

Select All    Deselect All
 |   | 

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/acutrialsocom/public_html/refbase-ocom/includes/ on line 5275
  Record Links
Author (up) Xiao Wu; Cuihong Zheng; Xiaohu Xu; Pei Ding; Fan Xiong; Man Tian; Ying Wang; Haoxu Dong; Mingmin Zhang; Wei Wang; Shabei Xu; Minjie Xie; Guangying Huang url  openurl
  Title Electroacupuncture for Functional Constipation: A Multicenter, Randomized, Control Trial Type of Study Journal Article
  Year 2017 Publication Evidence-based Complementary & Alternative Medicine (eCAM) Abbreviated Journal Evidence-based Complementary & Alternative Medicine (eCAM)  
  Volume Issue Pages 1-10  
  Keywords CONSTIPATION -- Treatment; Constipation; Defecation; Electroacupuncture; GASTROINTESTINAL agents; MEDICAL cooperation; ORAL medication; PATIENT satisfaction; QUALITY of life; Research; SAMPLING (Statistics); RANDOMIZED controlled trials; TREATMENT effectiveness  
  Abstract Background and Aim. To investigate the efficacy and safety of electroacupuncture (EA) with different current intensities for functional constipation (FC) and to assess whether the effects of EA with different current intensities are superior to the mosapride. Methods. Patients with FC were randomly divided into low current intensity group (LCI), high current intensity group (HCI), and mosapride group (MC). The primary outcome was three or more spontaneous bowel movements (SBMs) per week and an increase of one or more SBMs from baseline during at least 3 of the 4 weeks. Results. The primary outcome was reached by 53.45%, 66.15%, and 52.24% of the patients who received LCI, HCI, and mosapride, respectively. EA can significantly improve the weekly SBMs and stool consistency and reduce straining severity ( p < 0.0001, all). HCI improved the quality of life better than mosapride ( p < 0.05) and reduced the proportion of severe constipation more than LCI and mosapride ( p < 0.05, both). Conclusions. EA is effective and safe at both current intensities for FC; therapeutic effects of LCI and HCI are not superior to mosapride. EA is superior to mosapride in improving patients’ life quality and satisfaction level of treatment; EA has fewer adverse events than mosapride.  
  Publisher Hindawi Publishing Corporation
  Language Number of Treatments  
  Treatment Follow-up Frequency Number of Participants  
  Time in Treatment Condition
  Disease Category OCSI Score  
  Notes Accession Number: 121086632; Source Information: 1/31/2017, p1; Subject Term: CONSTIPATION -- Treatment; Subject Term: CONSTIPATION; Subject Term: DEFECATION; Subject Term: ELECTROACUPUNCTURE; Subject Term: GASTROINTESTINAL agents; Subject Term: MEDICAL cooperation; Subject Term: ORAL medication; Subject Term: PATIENT satisfaction; Subject Term: QUALITY of life; Subject Term: RESEARCH; Subject Term: SAMPLING (Statistics); Subject Term: RANDOMIZED controlled trials; Subject Term: TREATMENT effectiveness; Subject Term: ; Number of Pages: 10p; ; Illustrations: 1 Diagram, 5 Charts, 2 Graphs; ; Document Type: Article; Approved no  
  Call Number OCOM @ refbase @ Serial 2239  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: